At least 39 drugs developed and marketed by biotech companies are anticipated to have more than $500 million in sales in 2012. This compares to at least 35 in 2011. While Adderall XR dextroamphetamine/amphetamin from Shire plc (LSE:SHP; NASDAQ:SHPG) is no longer expected to post sales above $500 million, five new drugs have entered the list this year: Angiomax bivalirudin from The Medicines Co. (NASDAQ:MDCO); Cimzia ertolizumab pegol from UCB Group (Euronext:UCB); Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN); Prolia/Xgeva denosumab from Amgen Inc. (NASDAQ:AMGN); and Replagal agalsidase alfa from Shire plc (LSE:SHP; NASDAQ:SHPG).

Product sales as reported by companies listed below, unless otherwise noted. Included are drugs developed by biotechs that were acquired - Amylin Pharmaceuticals LLC; Cephalon Inc.; Genentech Inc.; Genzyme Corp.; MedImmune LLC; and OSI Pharmaceuticals LLC - but still maintain a separate commercial presence from their acquirer.

(A) Global in-market sales; (B) Does not include Europe since partner Johnson & Johnson (NYSE:JNJ) does not report sales; (C) Sales of Synagis are seasonal, extrapolation assumes 4Q12 sales at least match 4Q11 sales; (D) U.S. sales; (E) 2011 and 2012 ex-U.S. sales estimated to be about one-quarter of U.S. sales, the same percentage seen in 2010; (F) 2011 sales estimated based on 1Q, 2Q and 4Q figures, since 3Q sales were not reported by Cephalon or Teva Pharmaceutical Industries Inc. (NASDAQ:TEVA); $M

Company

2011 sales

2012 9-mo sales

2012 run rate

Proj chg

Amgen Inc. (NASDAQ:AMGN)/Pfizer Inc. (NYSE:PFE)/Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)

Enbrel etanercept

$7,894.8

$6,258.2

$8,344.3

6%

Biogen Idec Inc. (NASDAQ:BIIB)/Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)

Rituxan rituximab (MabThera)

$6,393.5

$5,316.9

$7,089.2

11%

Biogen Idec Inc. (NASDAQ:BIIB)/Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)

Herceptin trastuzumab

$5,592.9

$4,714.8

$6,286.4

12%

Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)

Avastin bevacizumab

$5,634.4

$4,583.9

$6,111.9

8%

Amgen Inc. (NASDAQ:AMGN)

Neulasta pegfilgrastim

$3,952.0

$3,098.0

$4,130.7

5%

Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)/ Novartis AG (NYSE:NVS; SIX:NOVN)

Lucentis ranibizumab

$3,671.5

$2,984.0

$3,978.7

8%

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)

Copaxone glatiramer acetate

$3,570.0

$2,937.0

$3,916.0

10%

Celgene Corp. (NASDAQ:CELG)

Revlimid lenalidomide

$3,208.2

$2,765.0

$3,686.7

15%

Gilead Sciences Inc. (NASDAQ:GILD)

Atripla efavirenz/ emtricitabine/tenofovir

$3,224.5

$2,657.0

$3,542.7

10%

Gilead Sciences Inc. (NASDAQ:GILD)

Truvada emtricitabine/tenofovir

$2,875.1

$2,348.4

$3,131.2

9%

Biogen Idec Inc. (NASDAQ:BIIB)

Avonex interferon beta-1a

$2,686.6

$2,159.9

$2,879.9

7%

Amgen Inc. (NASDAQ:AMGN)

Aranesp darbepoetin alfa

$2,303.0

$1,551.0

$2,068.0

-10%

Amgen Inc. (NASDAQ:AMGN)

Epogen epoetin alfa

$2,040.0

$1,462.0

$1,949.3

-4%

Actelion Ltd. (SIX:ATLN)

Tracleer bosentan

$1,620.6

$1,203.1

$1,604.1

-1%

Biogen Idec Inc. (NASDAQ:BIIB)/ Elan Corp. plc (NYSE:ELN) (A)

Tysabri natalizumab

$1,510.6

$1,198.3

$1,597.7

6%

OSI Pharmaceuticals LLC/Astellas Pharma Inc. (Tokyo:4503)/ Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)

Tarceva erlotinib

$1,331.9

$1,052.1

$1,402.8

5%

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)/ Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508)/ Johnson & Johnson (NYSE:JNJ) (B)

Incivek telaprevir (Incivo/ Telavic)

$952.2

$1,004.2

$1,338.9

41%

Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)/ Novartis AG (NYSE:NVS; SIX:NOVN)

Xolair omalizumab

$1,120.0

$937.8

$1,250.4

12%

Amgen Inc. (NASDAQ:AMGN)

Prolia/Xgeva denosumab

$554.0

$851.0

$1,134.7

105%

UCB Group (Euronext:UCB)

Keppra levetiracetam

$1,251.1

$838.2

$1,117.6

-11%

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)

Soliris eculizumab

$783.4

$813.6

$1,084.8

38%

Shire plc (LSE:SHP; NASDAQ:SHPG)

Vyvanse lisdexamfetamine

$805.0

$773.3

$1,031.1

28%

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX)/ Bayer AG (Xetra:BAY)

Nexavar sorafenib

$1,008.2

$742.8

$990.4

-2%

MedImmune LLC/AstraZeneca plc (LSE:AZN; NYSE:AZN) (C)

Synagis palivizumab

$975.0

$535.0

$946.0

-3%

Amgen Inc. (NASDAQ:AMGN)

Sensipar cinacalcet (Mimpara)

$808.0

$694.0

$925.3

15%

Endo Health Solutions Inc. (NASDAQ:ENDP)

Lidoderm lidocaine

$825.2

$676.3

$901.7

9%

Cubist Pharmaceuticals Inc. (NASDAQ:CBST)

Cubicin daptomycin

$735.5

$629.2

$838.9

14%

Gilead Sciences Inc. (NASDAQ:GILD)

Viread tenofovir

$737.9

$622.0

$829.3

12%

Genzyme Corp./Sanofi (Euronext:SAN; NYSE:SNY)

Renagel/Renvela sevelamer

$537.5

$611.9

$815.9

52%

Celgene Corp. (NASDAQ:CELG)

Vidaza azacitidine

$705.3

$607.1

$809.5

15%

Genzyme Corp./Sanofi (Euronext:SAN; NYSE:SNY)

Cerezyme imiglucerase

$571.1

$593.9

$791.9

39%

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Eylea aflibercept

$24.8

$561.9

$749.2

2921%

UCB Group (Euronext:UCB)

Cimzia ertolizumab pegol

$404.1

$429.4

$572.5

42%

Astellas Pharma Inc. (Tokyo:4503)/Rapidscan Pharma Solutions Inc./Gilead Sciences Inc. (NASDAQ:GILD) (D)

Lexiscan regadenoson

$521.0

$428.0

$570.7

10%

Amylin Pharmaceuticals LLC/ Bristol-Myers Squibb Co. (NYSE:BMY) (E)

Byetta exenatide

$657.4

$404.2

$539.0

-18%

The Medicines Co. (NASDAQ:MDCO)

Angiomax/Angiox bivalirudin

$483.9

$393.0

$524.0

8%

Cephalon Inc./ Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) (F)

Provigil modafinil

$1,108.0

$392.0

$522.7

-53%

Shire plc (LSE:SHP; NASDAQ:SHPG)

Replagal agalsidase alfa

$475.2

$379.3

$505.7

6%